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1ABSTRACT
Prevalence and mechanisms of carbapenem resistance
in Acinetobacter spp. isolated from South Korea
Woonhyoung Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Seok Hoon Jeong)
The persistent increase of carbapenem-resistant Acinetobacter spp. is a 
global issue. This study was performed to investigate the prevalence of 
carbapenem-resistant Acinetobacter spp. and to determine resistance 
mechanisms in Korea.
A total of 418 non-duplicate Acinetobacter clinical isolates were 
collected from 28 general hospitals in Korea from October to December 
2013. Species identification was performed using rpoB gene sequencing. 
Antimicrobial susceptibilities were determined by disk diffusion assays 
following CLSI guidelines. Genes encoding carbapenemases were 
amplified by PCR, and amplified products were directly sequenced.
Multilocus sequence typing (MLST) was used for characterizing isolates.
Of 407 collected isolates, 356 (87.5%) were identified as A. baumannii, 
and non-baumannii Acinetobacter (NBA) isolates were identified as A. 
nosocomialis (n = 26, 6.4%), A. pitti (n = 22, 5.4%), A. berezinae (n = 1), 
A. gyllenbergii (n = 1), and A. haemolyticus (n = 1).
While only 12.4% (44/356) and 11.8% (42/356) of A. baumannii clinical 
isolates were susceptible to imipenem and meropenem, respectively, 
susceptible rates of NBA clinical isolates to imipenem (43/58, 84.3%) 
and meropenem (43/58, 84.3%) were higher.
The blaOXA-23 gene was detected in 310 A. baumannii isolates, while the
2insertion sequence ISAba1 element associated with the blaOXA-51-like gene 
was detected in only 13 A. baumannii isolates. The blaOXA-58 gene was 
detected in 2 NBA isolates. The blaOXA-24 and blaOXA-182 genes were not 
detected in this study. The blaIMP-1 gene was detected in 1 NBA isolate. 
While A. baumannii acquired carbapenem resistance by producing 
OXA-23 carbapenemase or overproducing OXA-51 or both of them, A. 
nosocomialis and A. pitti acquired that by producing IMP-1 or OXA-58.
Of the 356 A. baumannii clinical isolates, 292 isolates were identified as 
clonal complex 92 (CC92) by MLST, and remaining isolates were 
identified as CC110 (n = 7), CC397 (n = 3), CC20 (n = 20), and other 
sequence types (STs, n = 34).
The isolates belonging to CC92 exhibited different antibiogram 
compared to the isolates not belonged to CC92. Of 292 CC92 isolates, 
only 1.4% (4 isolates) were susceptible to carbapenems. Of 66 isolates 
not belonged to CC92, 62.1% (41 isolates) were susceptible to 
carbapenems.
Regardless of belonging to CC92 or not, the blaOXA-23 gene was detected 
in 301 A. baumannii isolates (301/356, 84.6%).
OXA-23-producing A. baumannii clinical isolates not belonging to CC92 
and A. nosocomialis have emerged in Korea.
----------------------------------------------------------------------------------------
Key words : Acinetobacter, Carbapenem, OXA carbapenemase, 
Metallo-β-lactamase
3Prevalence and mechanisms of carbapenem resistance in Acinetobacter
spp. isolated from South Korea
Woonhyoung Lee
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Seok Hoon Jeong)
I. INTRODUCTION
Antimicrobial agents (antibiotics) are extremely important drugs to fight against 
bacterial infection.1 However, bacteria have increasingly been resisting to 
antimicrobial therapy.2 Resistance problem has relatively worsened in 
Gram-negative bacilli.3,4 Acinetobacter baumannii causes various nosocomial 
infections with high mortality, and the infection caused by multidrug-resistant A. 
baumannii is currently among the most difficult ones to treat.5 A few extensive 
reviews have been published on Acinetobacter bacteriology and infection.6-8 In 
most Asian countries, including Korea, Acinetobacter infections are relatively 
more prevalent and the organisms are more often resistant.9
Seven mechanisms of antibiotic resistance are known in Gram-negative bacteria: 
loss of porins, production of β-lactamases, increased expression of efflux pumps, 
presence of antibiotic-modifying enzymes, target site mutations, ribosomal 
mutations or modifications, metabolic bypass mechanisms, and a mutation in the 
lipopolysaccharide.10
Acinetobacter spp. are intrinsically less susceptible to antimicrobial agents than 
the species of Enterobacteriaceae.2 Outer membrane permeability of A. baumannii
is less than 5% compared with other Gram-negative bacilli, because of small 
number and size of porins.11 Porins are pore forming proteins on the outer 
membrane (OMP) of bacteria.2 Three OMPs (33-36 kDa, 29 kDa, and 43 kDa) 
have been reported to be missing in the imipenem-resistant strains of A. 
4baumannii.2 Decreased expression of OmpW was reported in a colistin-resistant A. 
baumannii mutant.2
All bacteria have efflux systems.2 The multidrug efflux pumps actively export 
multiple, structurally-distinct classes of antimicrobials out of the bacterial cell.2
The most common antimicrobials expelled by the efflux pumps are macrolides, 
tetracyclines and quinolones.11 Overexpression of efflux pump further increases 
resistance level.2 Among the six families of multidrug efflux systems, major 
facilitator superfamily (MFS) and resistance-nodulation-division (RND) family 
are often associated with antimicrobial resistance in A. baumannii.2 Tet(A) and 
Tet(B) pumps belong to the MFS, and confers resistance to tetracycline, and both 
tetracycline and minocycline, respectively.2 AdeM pump is a member of the 
multidrug and toxic compound extrusion (MATE) family, and confers resistance 
to norfloxacin, ofloxacin, ciprofloxacin, and gentamicin.11 AdeABC is a 
three-component efflux pump, where AdeA is the membrane fusion protein, AdeB 
is the multidrug transporter, and AdeC is the OMP.2 AdeABC pump belongs to the 
RND family and confers resistance to aminoglycosides, β-lactams, 
chloramphenicol, erythromycin and tetracyclines, and reduced susceptibility to 
fluoroquinolones.2
A. baumannii carries intrinsic blaAmpC genes encoding Acinetobacter-derived 
cephalosporinases which confer natural resistance to cefoxitin,2 as are many other 
species of Gram-negative bacilli.2,12 Inducible AmpC expression does not occur in 
A. baumannii, unlike that of AmpC enzymes found in other Gram-negative 
bacilli.2 Presence of upstream ISAba1 is involved in the overexpression of this 
gene, resulting in resistance to 3rd generation cephalosporins.13,14 A. baumannii
also naturally carries intrinsic blaOXA-51-like genes, and presence of upstream 
ISAba1 renders the organism resistant to carbapenems.2 ISAba1, ISAba2, ISAba3, 
and ISAba4 could increase expression of blaOXA-51-like genes.2 Increased 
expression of blaOXA-23 by the upstream ISAba10 was reported in a group of A. 
baumannii isolates.15
Carbapenem-resistant Acinetobacter spp. have been increasingly reported 
worldwide.16 It was reported that imipenem susceptibility decreased from 72.2% 
5in 2005 to 37.6% in 2009 among the worldwide collection of Acinetobacter spp.17
In a Korean nationwide study, the imipenem resistance rate of Acinetobacter spp. 
was 51% in 2009.18 OXA-type carbapenemases have emerged as the main 
resistance mechanism to carbapenems in Acinetobacter spp..7,8 OXA-type 
carbapenemases are categorized into 4 groups, including OXA-23-like, 
OXA-24-like, OXA-58-like, and OXA-51-like clusters.8
The prevalent blaOXA genes are known to vary significantly depending on the date 
and place of isolation.16 In the United Kingdom, it was reported that the proportion 
of isolates with ISAba1-associated blaOXA-51-like genes decreased significantly 
from 2003 to 2005, while those with blaOXA-23-like genes remained prevalent.
19 In 
Italy, isolates harboring the blaOXA-23-like gene emerged in 2007, replacing the 
previously prevalent blaOXA-58-like genes.20 A high prevalence of blaOXA-143 was 
reported in Brazil,21 which is where this novel gene was discovered.22 In 2005 
nationwide Korean surveillance, the majority of Acinetobacter isolates harbored 
either blaOXA-23-like or blaOXA-51-like genes.
18 In another study, a novel blaOXA-182
gene (GenBank no. JQ964242) whose encoded protein has 93% amino acid 
identity to the OXA-143 protein was detected.23
The aim of this study was to determine the prevalence and the spreading pattern of 
Acinetobacter spp. isolated from many hospitals in South Korea.
6II. MATERIALS AND METHODS
A total of 418 non-duplicate Acinetobacter clinical isolates were collected from 28 
general hospitals in Korea between October and December 2013. 
- Phylogenetic grouping based on partial rpoB gene sequencing: The 450 bp 
sequence (zone 2) of the rpoB gene was amplified using the primers Ac1005F 
(5′-GTGATAARATGGCBGGTCGT-3′) and Ac1598R 
(5′-CGBGCRTGCATYTTGTCRT-3′) as previously described.24 The phylogenetic 
relationship based on the rpoB zone 2 sequence was estimated using the 
neighbour-joining method in molecular evolutionary genetic analysis software.
- Antimicrobial Susceptibility Testing (Disk diffusion method): Antimicrobial 
disks were dispensed onto the surface of the inoculated Mueller-Hinton agar plate. 
After 16 to 18 hours of incubation, the diameters of the zones of complete 
inhibition (as judged by the unaided eye) were measured, including the diameter 
of the disk.
- PCR and sequencing for genes encoding MBLs and OXA carbapenemases: 
Whole-cell lysates of the test organisms were used as templates for PCR 
ampliﬁcation. PCR experiments were carried out to detect the genes encoding 
MBLs and OXA carbapenemases. The PCR procedure initiated denaturation 
(94◦C for 5 min) consisted of 30 cycles of denaturation at 94◦C for 25 sec, 
annealing at 52◦C for 40 sec and extension at 72◦C for 50 sec, followed by a ﬁnal 
extension at 72◦C for 6 min.
- Multilocus sequence typing (MLST): MLST was performed using the method of 
Bartual et al.25 Fragments of seven housekeeping genes (gltA, gyrB, gdhB, recA, 
cpn60, gpi and rpoD) were ampliﬁed by PCR and sequenced. Allele numbers were 
assigned an ST after the distinct allele sequences were submitted to a dedicated 
database (www.pubmist.org).
7III. RESULTS
1. Of 407 collected isolates, 356 (87.5%) were identified as A. baumannii, and 
non-baumannii Acinetobacter (NBA) isolates were identified as A. nosocomialis
(n = 26, 6.4%), A. pitti (n = 22, 5.4%), A. berezinae (n = 1), A. gyllenbergii (n = 1), 
and A. haemolyticus (n = 1) (Table 1). 
Of the 356 A. baumannii clinical isolates, 292 isolates were identified as clonal 
complex 92 (CC92) by MLST, and remaining isolates were identified as CC110 (n 
= 7), CC397 (n = 3), CC20 (n = 20), and other sequence types (STs, n = 34) (Table 
1).
8Table 1. Species & Strains
Species
Specimen
Total
Respiratory Blood Urine Pus Body fluid
n % n % n % n % n % n %
A. baumannii 252 89.0 21 65.6 25 92.3 54 90.0 5 83.3 356 87.5
CC92 210 71.9 16 5.5 18 6.2 44 15.1 4 1.4 292 82.0
CC110 7 100.0 - - - - - - - - 7 2.0
CC397 3 100.0 - - - - - - - - 3 0.8
CC447 12 60.0 1 5.0 2 10.0 4 20.0 1 5.0 20 5.6
Others 20 58.8 4 11.8 4 11.8 6 17.6 - - 34 9.6
A. nosocomialis 15 5.3 7 21.9 1 3.8 3 5.0 - - 26 6.4
A. pitti 14 4.9 4 12.5 1 3.8 2 3.3 1 16.7 22 5.4
A. berezinae 1 0.4 - - - - - - - - 1 0.2
A. gyllenbergii 1 0.4 - - - - - - - - 1 0.2
A. haemolyticus - - - - - - 1 1.7 - - 1 0.2
Total 283 100 34 100 28 100 60 100 6 100 415 100
Abbreviations: n, number.
92. While only 12.4% (44/356) and 11.8% (42/356) of A. baumannii clinical 
isolates were susceptible to imipenem and meropenem, respectively, susceptible 
rates of NBA clinical isolates to imipenem and meropenem were 84.3% (43/58) 
and 84.3% (43/58), respectively (Table 2). 
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Table 2. Antimicrobial susceptibilities (%) of A. baumannii and non-baumannii Acinetobacter clinical isolates
Antimicrobial 
agents
A. baumannii NBA
Total
CC92 CC110 CC397 CC20 Others Subtotal
A. 
nosocomialis
A. pittii
Other 
NBAs
Subtotal
(n=292) (n=7) (n=3) (n=20) (n=34) (n=356) (n=26) (n=22) (n=3) (n=51) (n=407)
Piperacillin 0.3 0.0 0.0 15.0 75.0 8.7 57.7 40.9 100.0 52.9 14.0
Ticarcillin 0.7 0.0 0.0 45.0 88.9 12.0 80.8 86.4 100.0 84.3 20.9
Ampicillin-sulbactam 2.1 14.3 0.0 45.0 88.9 13.4 92.3 86.4 100.0 90.2 22.9
Piperacillin-tazobactam 0.7 0.0 0.0 40.0 88.9 11.7 76.9 90.9 66.7 82.4 20.4
Cefotaxime 0.0 0.0 0.0 0.0 8.3 0.8 3.8 18.2 0.0 9.8 1.7
Ceftazidime 0.3 14.3 0.0 85.0 91.7 14.5 92.3 86.4 100.0 90.2 23.8
Cefepime 2.4 14.3 0.0 45.0 88.9 13.7 69.2 86.4 100.0 78.4 21.6
Imipenem 1.4 0.0 0.0 45.0 88.9 12.6 80.8 86.4 100.0 84.3 21.4
Meropenem 0.7 0.0 0.0 45.0 88.9 12.0 80.8 86.4 100.0 84.3 20.9
Amikacin 18.2 0.0 0.0 95.0 94.4 29.6 80.8 86.4 100.0 84.3 36.4
Gentamicin 7.5 0.0 33.3 95.0 94.4 21.2 61.5 90.9 100.0 76.5 28.0
Tobramycin 14.0 0.0 100.0 95.0 94.4 27.1 73.1 86.4 66.7 78.4 33.4
Ciprofloxacin 0.3 0.0 0.0 45.0 91.7 12.0 65.4 90.9 100.0 78.4 20.1
Tetracycline 5.8 0.0 0.0 50.0 91.7 16.8 65.4 100 100.0 82.4 24.8
Trimethoprim-sulfamethoxazole 2.1 0.0 0.0 40.0 94.4 13.4 92.3 77.3 100.0 86.3 22.4
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Antimicrobial 
agents
A. baumannii NBA
Total
CC92 CC110 CC397 CC20 Others Subtotal
A. 
nosocomialis
A. pittii
Other 
NBAs
Subtotal
(n=292) (n=7) (n=3) (n=20) (n=34) (n=356) (n=26) (n=22) (n=3) (n=51) (n=407)
Colistin 99.7 100.0 100.0 100.0 100.0 99.7 100.0 100 100.0 100.0 99.8
Tigecycline 27.1 100.0 0.0 95.0 94.4 38.8 84.6 100 100.0 92.2 45.2
Abbreviations: NBA, non-baumannii Acinetobacter; CC, clonal complex.
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3. The blaOXA-23 gene was detected in 310 A. baumannii isolates, while the ISAba1
element associated with the blaOXA-51-like gene was detected in only 13 A. 
baumannii isolates. The blaOXA-58 gene was detected in 2 NBA isolates. The 
blaOXA-24 and blaOXA-182 genes were not detected in this study. The blaIMP-1 gene 
was detected in 1 NBA isolate (Table 3). While A. baumannii acquired 
carbapenem resistance by producing OXA-23 carbapenemase or overproducing 
OXA-51 or both of them. A. nosocomialis and A. pitti acquired carbapenem 
resistance by producing IMP-1 or OXA-58.
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Table 3. No. of Acinetobacter clinical isolates producing carbapenemases
Species
Carbapenem resistance determinant
Total
blaOXA-23 blaOXA-23 + ISAba1-blaOXA-51 ISAba1-blaOXA-51 blaOXA-58 blaIMP-1 non
A. baumannii CC92 278 9 3 0 0 2 292
CC110 6 0 1 0 0 0 7
CC397 3 0 0 0 0 0 3
CC20 11 0 0 0 0 9 20
others 3 0 0 0 0 31 34
Subtotal 301 9 4 0 0 42 356
NBA A. nosocomialis 4 0 0 2 1 21 26
A. pittii 0 0 0 1 1 20 22
Other NBAs 0 0 0 0 0 3 3
Subtotal 3 0 0 3 2 44 51
Total 301 9 4 3 2 86 407
Abbreviations: NBA, non-baumannii Acinetobacter; non, no carbapenem resistance determinant.
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4. CC92 comprised of ST191 (n = 148), ST208 (n = 38), ST219 (n = 1), ST357 (n 
= 50), ST358 (n = 1), ST368 (n = 4), ST369 (n = 13), ST451 (n = 16), ST737 (n = 
3),  ST858 (n = 4), ST784 (n = 12), and others comprised of ST* (n = 1); CC110 
comprised of ST229 (n = 5) and others comprised of ST* (n = 2); CC397 
comprised of ST* (n = 3); CC20 comprised of ST620 (n = 1) and other comprised 
of ST* (n = 19); Others comprised of ST359 (n = 1), ST454 (n = 1), ST707 (n = 1), 
ST739 (n = 1) , ST688 (n = 1), ST552 (n = 2) and ST* (n = 27). Novel STs found 
in this study are indicated (Table 4).
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Table 4. MLST of 358 A. baumannii isolates
CC
ST
Alleic type No. of
isolates
Total
gltA gyrB gdhB recA cpn60 gpi rpoD
CC92 191 1 3 3 2 2 94 3 148 292
208 1 3 3 2 2 97 3 38
219 1 3 3 2 2 101 3 1
357 1 12 3 2 2 145 3 50
358 1 3 3 2 2 145 3 1
368 1 3 3 2 2 140 3 4
369 1 3 3 2 2 106 3 13
373 1 12 12 11 4 103 3 1
451 1 3 3 2 2 142 3 16
737 1 31 3 2 2 158 3 3
858# 1 12 3 2 2 140 3 4
784# 1 3 3 2 2 107 3 12
* 1 3 3 2 2 94 21 1
CC110 229 1 15 2 28 1 107 32 5 7
* 1 15 120 28 1 107 32 1
* 1 15 2 28 48 107 32 1
CC397 * 10 53 4 6 4 98 5 1 3
* 10 53 4 64 4 98 5 1
* 10 53 132 6 4 98 5 1
CC20 620 1 1 13 12 4 16 2 1 20
* 1 1 13 60 4 16 2 1
* 1 15 13 43 4 106 2 1
* 1 15 13 60 4 106 2 12
* 1 15 13 60 4 163 2 5
Other 359 21 38 127 1 4 146 43 1 34
454 1 17 80 28 35 97 30 1
701 1 34 62 31 4 61 45 1
739 1 15 59 28 4 144 45 1
* 1 12 56 36 4 149 45 1
* 1 35 12 6 4 94 3 1
* 1 47 67 28 1 103 6 1
* 1 12 3 28 1 107 4 1
688 1 15 135 6 35 187 45 1
* 1 56 13 48 4 107 6 1
* 1 90 67 60 1 94 4 1
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CC
ST
Alleic type No. of
isolates
Total
gltA gyrB gdhB recA cpn60 gpi rpoD
Other * 1 90 38 6 26 187 5 1
* 1 12 13 33 4 173 2 1
* 1 17 82 39 1 107 7 1
* 1 93 139 6 1 153 6 1
* 1 34 59 28 4 157 6 1
* 2 38 42 36 4 178 41 1
* 18 93 135 6 4 187 50 1
* 21 35 2 28 22 145 4 1
552 21 35 2 28 1 145 4 2
* 21 12 2 28 1 84 5 1
* 21 48 58 42 36 140 4 1
* 21 35 2 28 1 145 3 1
* 23 61 134 26 4 160 4 1
* 24 17 71 60 1 153 52 1
* 33 31 2 28 1 144 5 2
* 33 58 11 36 11 153 40 1
* 35 15 13 12 4 163 2 1
* 36 12 59 28 4 94 4 1
* 37 15 58 42 4 98 41 1
* 49 68 3 53 41 145 58 1
* 29 46 67 6 30 195 4 1
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5. The isolates belonging to CC92 exhibited different antibiogram compared to the 
isolates not belonged to CC92. Of 292 isolates of CC92, only 1.4% (4 isolates) 
was susceptible to carbapenems. Of 66 isolates not belonged to CC92, 62.1% (41 
isolates) was susceptible to carbapenems. Regardless of belonging to CC92 or not, 
the blaOXA-23 gene was detected in 301 A. baumannii isolates (301/356, 84.6%). 
Carbapenem susceptibility patterns were summarized according to ST in A. 
baumannii isolated (Table 5).
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Table 5. Carbapenem susceptibility patterns according to ST in A. baumannii isolated.
Clonal 
Complex
ST
No. of 
isolates
No. (%) of 
carbapenem-susceptible isolates
Carbapenem-resistance determinant
blaOXA-23 blaOXA-23 + ISAba1-blaOXA-51 ISAba1-blaOXA-51
CC92 ST191 147 2 (1.4) 144 3
ST208 38 0 (0) 37 1
ST219 1 0 (0) 1
ST357 50 0 (0) 50
ST358 1 0 (0) 1
ST368 4 0 (0) 4
ST369 13 0 (0) 5 5 3
ST373 1 0 (0) 1
ST451 16 0 (0) 16
ST737 3 0 (0) 3
* 4 0 (0) 4
* 12 0 (0) 12
Subtotal 290 2 (0.7) 278 9 3
Non-CC92 21 0 (0) 20 0 1
Abbreviations: Non-CC92, A. baumannii clinical isolates not belonging to CC92
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IV. DISCUSSION
OXA-type β-lactamases are molecular class D enzymes.26 OXA-type β-lactamases 
include narrow spectrum, extended-spectrum, and carbapenem-hydrolyzing ones.2
Of the OXA type β-lactamases, those with carbapenemase activity are the most 
concerned.2 The first OXA-type carbapenemase, OXA-23, was detected in 1985 
from an A. baumannii strain from Scotland.2 The blaOXA-23 gene was located on 
transferable plasmid.2 Four main groups of OXA carbapenemases include 
OXA-23-like, OXA-40-like, OXA-51-like, and OXA-58 enzymes.27
An outbreak of A. baumannii with OXA-23 was first reported at a Korean hospital 
in 2003 involving 36 patients.28 At another hospital in 2006-2007, all 49 isolates of 
A. baumannii with OXA-23 were found to have identical or closely related PFGE 
patterns, indicating that rapid increase of this determinant was due to clonal 
spread.29 In a Korean surveillance study in 2000-2001, only 27 of 267 (10.1%) 
imipenem-nonsusceptible Acinetobacter spp. isolates had MBLs.30 In another 
study in 2005,18 vast majority of imipenem resistance in Acinetobacter spp. 
isolates were due to OXA carbapenemase production: among the 144 
imipenem-resistant isolates only 19.4% had MBLs, whereas 74.3% had OXA 
carbapenemases.
Prevalent types of OXA carbapenemase varied significantly depending on reports 
in Korea.2 In a surveillance study in 2005,18 among the 105 imipenem-resistant 
isolates of A. baumannii, 47 had blaOXA-23-like and 56 had upstream 
ISAba1-associated blaOXA-51-like genes. In another study in 2007,23 among 178 
isolates of A. baumannii, isolates with blaOXA-23-like genes were more prevalent 
(80%) than those with ISAba1-asssociated blaOXA-51-like genes (12%). It is of an 
interest to note in this study that 12 isolates had a novel blaOXA-182 which is related 
to blaOXA-143, first reported in Brazil in 2004.22 At a Taiwanese regional hospital, 
among imipenem-resistant A. baumannii isolates, blaOXA-23-like gene was detected 
in only 2 of 97 isolates in 2005 and 2006, but the gene was detected in 24 of 38 
isolates in 2007.31 Presence of an identical PFGE type in 18 of the 38 isolates 
indicated that the rapid increase was due to outbreaks. In a study, among 544 
Acinetobacter isolates collected from 10 Asia Pacific countries in 2006-2007,32
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230 (42.3%) were nonsusceptible to carbapenems and OXA-23 was detected in 
134 of 156 A. baumannii isolates from China, Hong Kong, India, Korea, 
Singapore, and Thailand. A. baumannii isolates from China, Indonesia, Taiwan 
and Thailand carried other OXA carbapenemase: OXA-24/40 (n=5), OXA-58 
(n=2), OXA-23 plus OXA-58 (n=11), OXA-24 plus OXA-58 (n=1), and OXA-23 
plus OXA-24/40 plus OXA-58 (n=3). PFGE showed clonal dissemination of OXA 
carbapenemase-producing A. baumannii isolates within medical centers among 
different countries.
Carbapenems, colistin, and tigecycline were active against over 80% of A. 
baumannii complex isolated in 2000.33 A high colistin resistance rate of 30.6% 
among A. baumannii isolates from 2 Korean hospitals34 indicated necessity of 
colistin susceptibility testing in other settings.
In recent years, Acinetobacter spp. have been described as important pathogens in 
outbreaks of nosocomial infection worldwide, especially in intensive care units.6
In particular, the species A.baumannii has presented an increased rate of 
antimicrobial resistance.8,35 Carbapenems, once regarded as the treatment of 
choice for infections caused by Acinetobacter spp., are no longer effective in some 
cases.8 The main mechanism of carbapenem resistance among Acinetobacter spp. 
is the production of β-lactamases, in particular class D β-lactamases 
(oxacillinases), associated with promoter gene sequence ISAba1.35 Among 
oxacillinases, the most prevalent one is blaOXA-23, identified in mobile genetic 
elements.36 Chromosomally located blaOXA-51 genes, in turn, do not always confer 
carbapenem resistance but are used to identify A. baumannii, as it is believed to be 
intrinsic to this species.37-39
Traditionally, the blaOXA-23 and blaOXA-51 genes are associated with A. baumannii
only, but recently some authors have described the presence of such genes in 
non-A. baumannii species.36 The blaOXA-23 gene was found in A. pittii
(Acinetobacter genomic species 3) in the Irish Republic in 2006 and in A. 
nosocomialis (Acinetobacter genomic species 13TU) in South Korea and Thailand 
in 2012.40,41 Moreover, blaOXA-51 preceded by ISAba1 has been found in 
carbapenem-resistant A. nosocomialis in Taiwan.42
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The presence of oxacillinase genes in non-A. baumannii isolates had already been 
described in studies from China, South Korea, and Singapore, which underscores 
the potential clinical significance of these species.36,40-43
More generally, it is apparent that the population structure of A. baumannii
comprises three major international lineages, named European clones I, II, and 
III.44,45 A subgroup of European clone II involving clonal complex (CC) 92 has 
spread globally46 and is widespread in China47 and Korea48; it is also recorded in 
Australia.49
Although ST92 has been the global epidemic clone among 
carbapenem-non-susceptible A. baumannii,50 13 of 14 
carbapenem-non-susceptible A. baumannii isolates belonged to ST208 or its single 
variant ST219, the member of CC92 in a study.51 The fact that the isolates 
carrying blaOXA-66 belonged to CC92 is compatible
51 with the finding that the 
isolates carrying blaOXA-66 often belonged to STs such as ST98 (formerly ST34) 
included in CC92, as demonstrated in a recent report.52 CC92 has increasingly 
been documented as a globally disseminated linage included in European clone II, 
often with multidrug resistance.46,49 The blaOXA-51-like gene can confer carbapenem 
non-susceptibility to the bacteria if ISAba1 providing promoter sequences for 
overexpression is located adjacent to blaOXA-51-like.53
There was a previously performed survey in 2008 to define the epidemiological 
traits of XDR-ABA in Korea.54 A total of 547 non-duplicated clinical isolates of 
Acinetobacter spp. were collected from 19 different hospitals in six provinces of 
Korea. The isolates were identified as ABA (n = 388, 70.9%), A. nosocomialis (n 
= 82, 15.0%), A. pittii (n = 62, 11.3%), A. berezinae (n = 13, 2.4%), and 
Acinetobacter genomospecies 14TU (n = 2, 0.4%) by rpoB gene sequencing. 
While 70% (272/388) of ABA isolates exhibited non-susceptibility to imipenem 
and/or meropenem, only 6.9% (11/159) of non-baumannii Acinetobacter (NBA) 
isolates exhibited that. ABA and NBA acquired carbapenem resistance by 
different mechanisms. While XDR-ABA clinical isolates acquired carbapenem 
resistance by production of OXA-23 carbapenemase (62.1%, 169/272) or 
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overproduction of chromosomal OXA-51-like carbapenemase (32.7%, 89/272) or 
both of them (5.1%, 14/272), all XDR-NBA clinical isolates acquired that by 
production of IMP-1 (n = 6) or VIM-2 (n = 4) MBL, with the exception of an A. 
pitti isolate producing OXA-23. MLST experiments following the Bartual scheme 
on 388 ABA isolates identified 57 different STs. Interestingly, all 272 XDR-ABA 
isolates were identified as CC92 (ST92, n = 159; ST75, n = 64; ST137, n = 3; 
ST138, n = 38; and ST69, n = 8). The study showed that XDR-ABA CC92 
producing OXA-23 and/or overproducing OXA-51-like have clonally 
disseminated in Korea.
Compared to the previous study54, proportion of XDR-ABA isolates producing 
OXA-23 has increased from 47.2% (183/388) to 87.1% (310/356), while that of 
XDR-ABA isolates overproducing OXA-51-like has decreased from 26.5% 
(103/388) to 3.7% (13/356). XDR-NBA clinical isolates acquired carbapenem 
resistance by production of OXA-23 (A. nosocomialis, n = 4), OXA-58 (A. 
nosocomialis, n = 1; A. pittii, n = 1), or IMP-1 (A. pittii, n = 1). Compared to the 
previous survey, the proportion of MBL-producing NBA has decreased from 6.3% 
(10/159) to 2.0% (1/51). ABA clinical isolates were identified as Bartual CC20 
(5.6%, 20/356), CC92 (82.0%, 292/356), CC110 (2.0%, 7/356), CC397 (0.9%, 
3/356), and other 32 different STs (9.6%, 34/356) by MLST experiments. 
OXA-23-producing ABA isolates were identified as Bartual CC20 (3.5%, 11/310), 
CC92 (93.0%, 287/310), CC110 (1.9%, 6/310), CC397 (1.0%, 3/310), and other 3 
different STs (1.0%, 3/310), and OXA-51-like-overproducing ABA isolates were 
identified as Bartual CC92 (n = 12) and CC110 (n = 1).
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V. CONCLUSION
The results show that XDR-ABA producing OXA-23 carbapenemase has further 
disseminated in Korea during past 5 years. While all XDR-ABA isolates collected 
in 2008 were identified as CC9254, those collected in this study were identified as 
diverse clones. There is no evidence whether XDR-ABA of non-CC92 got into 
Korea from foreign countries or the strains acquired OXA-23 gene by horizontal 
transfer in this country. However, diversification of OXA-23-producing 
XDR-ABA strains in Korea might be a signal for further dissemination of the 
microorganisms in Korea.
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ABSTRACT(IN KOREAN)
국내에서 분리된 Acinetobacter 균속의 carbapenem계 항균제 내성
현황 및 기전
<지도교수 정석훈>
연세대학교 대학원 의학과
이 운 형
최근 Acinetobacter 균속에서 carbapenem계 항균제에 대한 내성률
이 현저히 증가하고 있다. 본 연구는 국내에서 분리된
Acinetobacter 균속의 carbapenem계 항균제 내성 기전 및 역학을
조사하고자 한다. 
본 연구에는 2013년 10월부터 12월까지 전체 28 대학 및 종합병
원에서 본 연구에 참여하였다. 연구기간 중 수집된 Acinetobacter 
균주는 전체 418주이었다. Acinetobacter 균속의 동정은 rpoB gene
의 염기서열 분석을 통하여 확인하였다. 항균제의 최소억제농도
(minimum inhibitory concentration, MIC)는 CLSI 한천희석법으로 측
정하였다. Carbapenemase의 유전형을 고안된 primer를 사용하여
PCR로 확인한다. MLST 등을 이용하여 분자역학적 성상을 규명
하였다.
본 연구를 통해 수집된 Acinetobacter 407주 중 A. baumannii로 동
정된 것은 356주 (87.5%)이었다. Non-baumannii 
Acinetobacter(NBA) 가운데 A. nosocomialis 26주 (6.4%), A. pitti 22
주 (5.4%), A. berezinae 1주, A. gyllenbergii 1주, 그리고 A. 
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haemolyticus 1주이었다.
전체 수집된 A. baumannii 356주 가운데 44주(12.4%)가 imipenem 
감수성이었고, 42주 (11.8%)가 meropenem 감수성이었다. NBA 58
주 중 imipenem 및 meropenem 감수성인 균주는 각각 43주
(84.3%), 43주(84.3%)로 높았다.
A. baumannii로 확인된 310주는 blaOXA-23 유전자를 보유하고
있었고, A. baumannii 13주에서만 염색체성 OXA-51 유전자의 상
류에 ISAba1이 확인되었다. NBA 2주는 blaOXA-58 유전자를 보유
하고 있었다. 본 연구에서는 blaOXA-24 와 blaOXA-182 유전자는 확인
되지 않았다. NBA 1주는 blaIMP-1 유전자를 보유하고 있었다. A. 
baumannii의 carbapenem 내성 기전은 OXA-23과 OXA-51 
carbapenemase의 생성 및 과발현에 의한 반면, A. nosocomialis 와
A. pitti 는 IMP-1 또는 OXA-58에 의했다.
A. baumannii로 확인된 356주 중 clonal complex(CC) 92 292주, 
CC110 7주, CC397 3주, CC20 20주, 그리고 그외 34주로 MLST에
의해 분자역학적 성상이 규명되었다.
CC92에 속한 균주의 antibiogram은 CC92에 속하지 않은 균주와
다른 성상을 보였다. CC92 292주 중 4주(1.4%)만 carbapenem감수
성이었다. 비CC92 66주 중 41주(62.1%)가 carbapenem감수성이었
다.
CC92 여부와 상관없이, A. baumannii 356주 중 301주가 blaOXA-23 
유전자를 보유하였다. CC92에 속하지 않은 OXA-23 
carbapenemase를 생산하는 A. baumannii균주와 A. nosocomialis가
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국내에 증가하고 있었다.
----------------------------------------------------------------------------------------
핵심되는 말 : Acinetobacter, Carbapenem, OXA carbapenemase, 
Metallo-β-lactamase
